The rising prevalence of chronic diseases is driving an increased demand for fluid connectors across various aspects of healthcare. For instance, according to the World Health Organization (WHO), by 2050, chronic diseases such as cardiovascular issues, cancer, diabetes, and respiratory conditions are projected to constitute a dominant 86% of the ninety million global deaths annually. This represents a significant 90% increase from the 2019, emphasizing the impending health challenges the world will confront.
Thus, these connectors are crucial for continuous monitoring and management of these chronic conditions, facilitating safe and precise transfer of bodily fluids for real-time data collection.
The development of increasingly sophisticated infusion pumps, advanced diagnostic equipment, and continuous monitoring systems has profoundly transformed patient care while accelerating the growth of the fluid connectors market.
In the age of surging healthcare spending, the medical fluid connectors market stands at the nexus of progress. Investments in infrastructure, advanced tech, and a shared commitment to better care drive this pivotal industry's growth.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The global market size for healthcare fluid connectors value was USD 2.5 billion in 2022 and is projected to be USD 4.3 billion by 2032 attributed to the rising prevalence of chronic disorders, the increasing demand for advanced medical devices and technologies, and the growing healthcare expenditure.
Infusion therapy segment held a major market share of 27.2% in 2022 and is anticipated to record growth through 2032 owing to the increasing prevalence of chronic diseases such as cancer, respiratory conditions, autoimmune conditions, among others, that increase the demand for infusion therapy.
North America healthcare fluid connectors market revenue share was 41.3% and is set to witness robust growth through 2032 due to the growing prevalence of cancer, along with considerable product approval rate from regulatory authorities such as the FDA.
Medtronic plc, Parker Hannifin Corporation, Becton, Dickinson and Company, Saint-Gobain, Nordson Corporation, Teleflex Medical, SMC Corporation, Qosina, B. Braun Melsungen AG, and IDEX Corporation.